Search Bar & Filters
Found 33 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.
Actively Recruiting
This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.
Actively Recruiting
Researchers are evaluating the efficacy of dotinurad in lowering serum uric acid sUA levels in adults with gout who cannot tolerate xanthine oxidase inhibitors XOI or have failed uricase treatment. This Phase 2, randomized, double-blind, placebo-controlled study focuses on participants aged 18 to 75 with gout diagnosed for at least one year, assessing dotinurads ability to reduce sUA by Week 24. Participants are assigned to one of two groups one group receives dotinurad for 36 weeks, divided into a 24-week initial treatment period followed by a 12-week continuation. The other group takes placebo for the first 24 weeks and then switches to dotinurad for the final 12 weeks. Dotinurad is given orally as over-encapsulated tablets, while placebo capsules contain microcrystalline cellulose. This design allows comparison of dotinurad with placebo before all participants receive the active drug. During the study, participants undergo regular assessments including serum uric acid measurements at various timepoints up to Week 40. Researchers monitor the percentage of participants achieving target sUA levels, changes from baseline sUA, and treatment-emergent adverse events. Female participants of childbearing potential must have pregnancy tests and follow contraception requirements. The trial is expected to complete by August 2027, providing detailed safety and efficacy data over the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.
Actively Recruiting
Researchers are studying the effectiveness of dotinurad compared to allopurinol in lowering serum uric acid levels in adults with tophaceous gout. This Phase 3, randomized, double-blind trial focuses on adults aged 18 to 75 years diagnosed with gout for at least one year who have measurable tophi. The study aims to evaluate how well dotinurad lowers uric acid at Week 24 compared to allopurinol. Participants are divided into two groups. One group stops their current allopurinol and takes study-provided allopurinol once daily up to Week 76. The other group stops their prior allopurinol and starts dotinurad, beginning with 1 mg daily for the first 4 weeks, increasing to 2 mg daily for 8 weeks, then 4 mg daily through Week 76. Both treatments involve oral capsules taken once a day. This approach allows comparison of the two drugs effects over an extended treatment period. During the study, participants will have regular assessments to monitor serum uric acid levels, tophi response, and gout flare frequency up to Week 80. Safety is tracked by recording any adverse events. Data collected will include changes in uric acid, tophi area, and flare rates. Participants remain in the study for over a year, with frequent visits for evaluations and treatment adherence checks.
Actively Recruiting
Researchers are evaluating the effect of LY3457263 compared with placebo on hemoglobin A1c HbA1c levels in adults with type 2 diabetes who have not reached their HbA1c goals despite stable treatment with semaglutide or tirzepatide. This phase 2, double-blind study aims to better understand how LY3457263 impacts blood sugar control in this population. Participants will receive once-weekly subcutaneous injections of either LY3457263 at one of three doses or a placebo, while continuing their stable dose of semaglutide or tirzepatide. The treatment period lasts 24 weeks, during which participants blood sugar and body weight changes will be monitored. The study includes a randomized, parallel-group design comparing these interventions. During the approximately 9-month study, participants will undergo assessments including measurements of HbA1c, fasting serum glucose, and body weight at baseline and week 24. Researchers will monitor safety and treatment effects throughout the study. Participants will have scheduled visits for treatment administration and evaluation, with the primary focus on HbA1c change from baseline at 24 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of elismetrep compared with a placebo for treating acute migraine attacks. This randomized, double-blind, phase III trial is conducted at multiple outpatient centers and sponsored by TriGemX Bio, Inc. The study focuses on adults aged 18 to 75 years who experience moderate to severe migraines lasting 4 to 72 hours, with a history of at least 2 but no more than 10 migraine attacks per month. Participants are randomly assigned to one of three groups elismetrep 10 mg, elismetrep 20 mg, or placebo. All treatments are taken orally during a migraine attack. The trial uses a parallel study design and is triple-blinded to ensure unbiased results. The main study period extends until February 2027, with participants monitored for responses two hours after dosing. During the study, participants will complete questionnaires and use an electronic diary on their smartphones to track migraine symptoms and treatment effects. Researchers will assess outcomes such as pain freedom, relief from bothersome symptoms, and functional disability at two hours post-dose. Additional evaluations include monitoring for adverse events up to eight days after dosing. Participants must follow the study schedule and complete all trial procedures to help assess elismetreps potential as an acute migraine treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NEXAGON4 lufepirsen ophthalmic gel in people with persistent corneal epithelial defects PCED, a condition where the corneal surface does not heal properly. This randomized, double-masked, vehicle-controlled study aims to understand how well NEXAGON works in treating PCED and its durability after treatment. This Phase 2 trial is sponsored by Glaukos Corporation and is conducted at multiple centers. Participants will be randomly assigned to receive one of three treatments applied topically to the eye once a week for 4 to 8 weeks a high dose of lufepirsen, a low dose of lufepirsen available only at EU sites, or a vehicle gel without the active drug. After the treatment period, a 4-week follow-up will monitor the condition. If the corneal defect does not heal or the healing is not maintained for 28 days, participants may enter an open-label treatment phase with NEXAGON for an additional 8 weeks. During the study, participants will undergo screening to confirm eligibility, receive weekly treatment applications, and be monitored for safety and healing progress. Researchers will assess corneal re-epithelialization and its durability as the main outcome. The total study participation includes the screening, up to 8 weeks of treatment, 4 weeks of follow-up, and possibly an 8-week open-label extension. Safety, efficacy, and healing durability will be closely observed throughout these periods.
1-10 of 33
1